Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Schedules Q4 2021 Earnings Release and Conference Call

T.CPH

MISSISSAUGA, ON, March 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021 after market close on March 17, 2022. The Company will also host a conference call on Friday, March 18, 2022 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS


DATE: March 18, 2022


TIME: 8:30 a.m. ET


DIAL-IN NUMBER: (647) 794-4605 or (888) 204-4368


CONFERENCE ID: 1673781


REPLAY DIAL-IN: (888) 203-1112 (playback 1673781#)


Expires March 25, 2022


WEBCAST: https://produceredition.webcasts.com/starthere.jsp?ei=1533942&tp_key=62d3cb0b34

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/March2022/11/c2977.html